Alexion Pharmaceuticals (ALXN) Reiterated Buy at Nomura but EPS Expected to be Below Consensus
Tweet Send to a Friend
Nomura/Instinet analyst Christopher Marai reiterated a Buy rating and $165.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) ahead of 3Q19 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
